drugset / Trial / NCT02921984

Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors

NCT02921984

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The role of postoperative concurrent chemotherapy (CCT) has not been established for salivary gland tumors (SGTs). This prospective study was conducted to evaluate the feasibility and safety of customized CCT regimens based on the gene targets of SGTs.

Timeline

Start
2013-09
Primary completion
2016-12
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 70 mg/m2
Subject Docetaxel Small molecule 80 mg/m2
Subject Pemetrexed Small molecule 500 mg/m2